BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this trial is to assess clinical efficacy and safety of different
subcutaneous doses of BI 655066 in adult patients with chronic plaque psoriasis in order to
select doses for further clinical trials.